Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

5613 - Nimotuzumab-Cisplatin-Radiation versus Cisplatin-Radiation in HPV negative oropharyngeal cancer


30 Sep 2019


Poster Display session 3


Tumour Site

Head and Neck Cancers


Kumar Prabhash


Annals of Oncology (2019) 30 (suppl_5): v449-v474. 10.1093/annonc/mdz252


K. Prabhash1, V.M. Patil2, V. Noronha1, A.P. Joshi1, A. Bhattacharjee3, V. Mathrudev1, A. Bhelekar1, K. Nawale1, J.P. Agarwal4, S. Ghosh-Laskar4, A. Budrukkar5, A. Mahajan6, A. Agarwal7, N. Purandare7, P. Chaturvedi8, P. Pai8, D. Chaukar8

Author affiliations

  • 1 Medical Oncology, Tata Memorial Hospital, 400012 - Mumbai/IN
  • 2 Medical Oncology, Tata Memorial Hospital Centre, 400068 - Mumbai/IN
  • 3 Section Of Biostatistics, Centre For Cancer Epidemiology, Tata Memorial Hospital, 400012 - Mumbai/IN
  • 4 Radiation Oncology, Tata Memorial Hospital, 400012 - Mumbai/IN
  • 5 Radiation Oncology, Tata Memorial Centre, 400012 - Mumbai/IN
  • 6 Radiodiagnosis, Tata Memorial Hospital Centre, 400012 - Mumbai/IN
  • 7 Nuclear Medicine, Tata Memorial Hospital, 400012 - Mumbai/IN
  • 8 Head And Neck Surgery, Tata Memorial Hospital, 400012 - Mumbai/IN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5613


Addition of nimotuzumab to weekly cisplatin and radiation improves outcomes in head and neck cancer. HPV-negative oropharyngeal cancer has unsatisfactory treatment outcomes and is a candidate for escalation of treatment. Hence we wanted to determine whether the addition of nimotuzumab to cisplatin-radiation can improve outcomes in these subsets of poor-risk tumors.


This was a subgroup analysis of a phase 3 randomized study. In this study locally advanced head and neck cancer patients undergoing definitive chemoradiation were randomly allocated to weekly cisplatin (30 mg/m2 IV )- radiation (66-70 Gy) {CRT arm} or nimotuzumab (200 mg weekly) -weekly cisplatin (30 mg/m2)-radiation (66-70 Gy) {NCRT arm}. The data for HPV-negative oropharyngeal cancer was extracted from the database of this study for the current analysis. HPV testing was done with p16 IHC staining and reported according to the CAP criteria. The outcomes assessed were progression-free survival (PFS), disease-free survival (DFS), locoregional control (LRC), and overall survival (OS). Interaction test was performed between the study arms and HPV status prior to doing any HPV-specific analysis for each of the studied outcomes. Kaplan Meier estimates for 2-year OS with 95% CI is provided. The hazard ratio was calculated using Cox regression analysis.


We had 187-HPV negative oropharyngeal cancers, 91-CRT arm and 96 in NCRT arm. The interaction test was significant for PFS (p = 0.000), locoregional control (p = 0.007) and overall survival (p = 0.002) but not for DFS (p = 0.072). The 2-year PFS was 31.5% (95%CI 21.5-42) in CRT arm versus 57.2% (95%CI 45.8-67.1) in NCRT arm (HR -0.54;95%CI 0.36-0.79, p = 0.002). While the 2-year LRC was 41.4 % (95%CI 29.8-52.6) in CRT arm versus in 60.4% (95%CI 48.7-70.2) in NCRT arm (HR -0.61;95%CI 0.4-0.94, p = 0.024). The addition of nimotuzumab also led to an improvement in OS from 39.0% (95%CI 28.4-49.6) to 57.6% (95%CI 46.3-67.4) (HR-0.63, 95%CI 0.43-0.92, p = 0.018).


The addition of nimotuzumab to weekly cisplatin-radiation improves outcomes inclusive of OS in HPV-negative oropharyngeal cancers.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

The authors.


Biocon Ltd, TRAC.


K. Prabhash: Research grant / Funding (institution): Dr. Reddy’s Laboratories Inc; Research grant / Funding (institution): Fresenius Kabi India Pvt Ltd; Research grant / Funding (institution): Alkem Laboratories; Research grant / Funding (institution): Natco Pharma Ltd; Research grant / Funding (institution): BDR Pharmaceutics Intl Pvt Ltd; Research grant / Funding (institution): Roche Holding AG. V. Noronha: Research grant / Funding (institution): Dr. Reddy’s Laboratories Inc; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Sanofi Aventis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.